SCHEMBL5873476

SCHEMBL5873476

CCOc1ccc(CCO)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CALM1 P0DP23 3/20 0.67
KDM4E B2RXH2 2/20 0.53
GAA P10253 1/20 0.53
MAPT P10636 1/20 0.53
TSHR P16473 1/20 0.53
ATM Q13315 2/20 0.51
MAPK1 P28482 1/20 0.51
HDAC1 Q13547 1/20 0.50
HDAC2 Q92769 1/20 0.50
S1PR1 P21453 1/20 0.49
S1PR3 Q99500 1/20 0.49
STAT3 P40763 1/20 0.49
POLB P06746 1/20 0.49
CYP19A1 P11511 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CA2 P00918 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9026143 0.91 S1PR1 (0.56) CALM1GAAMAPTTSHRMAPK1
SCHEMBL13098012 0.87 ATM (0.66) KDM4EMAPTATMSTAT3POLB
SCHEMBL296593 0.87 ATM (0.66) KDM4EMAPTATMSTAT3POLB
SCHEMBL29446268 0.87 ATM (0.66) KDM4EMAPTATMSTAT3POLB
SCHEMBL13098004 0.87 ATM (0.66) KDM4EMAPTATMSTAT3POLB
SCHEMBL462591 0.87 HDAC1 (0.52) CALM1KDM4EATMMAPK1HDAC1
SCHEMBL30714383 0.86 CALM1 (0.61) CALM1KDM4EGAAMAPTTSHR
SCHEMBL579760 0.86 CALM1 (0.61) CALM1KDM4EGAAMAPTTSHR
SCHEMBL680660 0.86 CALM1 (0.71) CALM1KDM4EGAAMAPTTSHR
SCHEMBL12124783 0.85 HDAC1 (0.53) CALM1HDAC1HDAC2S1PR1S1PR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US claimed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US claimed
WO-2011008597-A1 DIHYDROIMIDAZOISOQUINOLINE DERIVATIVES USEFUL AS PDE10 INHIBITORS SCHERING CORPORATION (US) 2011-01-20 WO disclosed
US-7767830-B2 Aminocyclohexyl ether compounds and uses thereof CARDIOME PHARMA CORP. (CA) 2010-08-03 US disclosed
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF CARDIOME PHARMA CORP. (CA) 2007-11-01 US disclosed
US-6989052-B1 Phase change ink printing process XEROX CORPORATION (US) 2006-01-24 US disclosed
US-20060004123-A1 PHASE CHANGE INK PRINTING PROCESS XEROX CORPORATION 2006-01-05 US disclosed
US-5686484-A ANTHELMINTICS, ACARICIDES, INSECTICIDES SANKYO CO., LTD. (JP) 1997-11-11 US disclosed
EP-0670720-A1 ENZYME INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1995-09-13 EP disclosed
WO-1994012165-A2 ENZYME INHIBITORS THE WELLCOME FOUNDATION LIMITED (GB) 1994-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254945-A1 AMINOCYCLOHEXYL ETHER COMPOUNDS AND USES THEREOF KCNH2, KCNC1, KCNH3 CALM1 1849/4885KDM4E 403/4885GAA 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.